Fidelity Disruptive Medicine ETF (FMED)
| Assets | $54.66M |
| Expense Ratio | 0.50% |
| PE Ratio | 39.93 |
| Shares Out | 2.22M |
| Dividend (ttm) | $0.11 |
| Dividend Yield | 0.46% |
| Ex-Dividend Date | Dec 20, 2024 |
| Payout Frequency | n/a |
| Payout Ratio | 18.38% |
| Volume | 1,959 |
| Open | 24.52 |
| Previous Close | 24.60 |
| Day's Range | 24.48 - 24.55 |
| 52-Week Low | 20.69 |
| 52-Week High | 26.79 |
| Beta | 1.01 |
| Holdings | 71 |
| Inception Date | Apr 16, 2020 |
About FMED
Fund Home PageThe Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is issued by Fidelity.
Top 10 Holdings
37.09% of assets| Name | Symbol | Weight |
|---|---|---|
| Boston Scientific Corporation | BSX | 5.40% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 5.28% |
| argenx SE | ARGX | 3.66% |
| Insulet Corporation | PODD | 3.60% |
| Veeva Systems Inc. | VEEV | 3.57% |
| Danaher Corporation | DHR | 3.54% |
| UCB SA | UCB | 3.28% |
| Penumbra, Inc. | PEN | 3.01% |
| Waystar Holding Corp. | WAY | 2.93% |
| Fidelity Securities Lending Cash Central Fund | n/a | 2.82% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2024 | $0.112 | Dec 24, 2024 |
| Jun 21, 2024 | $0.001 | Jun 25, 2024 |
Performance
FMED had a total return of -4.81% in the past year, including dividends. Since the fund's inception, the average annual return has been -0.88%.
News
First Look At FMED: Poor Performance Merits A Strong Sell Rating
Fidelity Disruptive Medicine ETF invests in innovative healthcare companies, focusing on sectors like robotic surgery, genomics, and advanced diagnostics, aiming to disrupt traditional medical practic...
Why traditional active managers are joining the ETF space
Greg Friedman, head of ETF management and strategy at Fidelity Investments, joins 'Halftime Report' to discuss a spike in ETF flows going to active management, Fidelity's decision to convert mutual fu...